Gohar Mushtaq, Ibrahim W. Hasani, Fouad Al-Daoud, A. Unnisa, Yahya A. Mutair, Samer Kabba, Yaser Alkanash
{"title":"Exploring nanotechnology-based approaches using miRNAs to treat neurodegenerative disorders","authors":"Gohar Mushtaq, Ibrahim W. Hasani, Fouad Al-Daoud, A. Unnisa, Yahya A. Mutair, Samer Kabba, Yaser Alkanash","doi":"10.1515/tjb-2023-0086","DOIUrl":null,"url":null,"abstract":"Abstract MicroRNAs (miRNAs) are small non-coding molecules that play a pivotal part in brain development and the processes of establishment and maintenance of dendrites and neurite outgrowth by modulating gene expression. Dysregulation of miRNAs has been linked with neurological disorders. Exogenous miRNAs are unstable in the plasma due to degradation by nucleases; hence, choosing a harmless and effective delivery mode is crucial in the quest for miRNA-based therapeutics to treat neurological disorders. This review aims to shed light on the emerging role of nanotechnology-based approaches using miRNAs to treat neurodegenerative disorders. Nanotechnology encompasses a broad spectrum of applications, one of which is its role in developing nanoscale drug delivery systems. Nanotechnology-based drug delivery systems have attracted the attention of researchers due to the superiority of this mode over conventional treatment systems in terms of their favorable attributes such as bio-compatibility, bio-degradability, extremely small size, and the ability to cross the blood-brain barrier. This review explores nanotechnology-based approaches using miRNAs highlighting the use of viral vectors as well as non-viral vectors (such as exosomes, liposome nanoparticles, gold and magnetic nanoparticles, dendrimer-based nanoparticles, polymeric nanoparticles) to treat neurodegenerative disorders.","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Biochemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/tjb-2023-0086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract MicroRNAs (miRNAs) are small non-coding molecules that play a pivotal part in brain development and the processes of establishment and maintenance of dendrites and neurite outgrowth by modulating gene expression. Dysregulation of miRNAs has been linked with neurological disorders. Exogenous miRNAs are unstable in the plasma due to degradation by nucleases; hence, choosing a harmless and effective delivery mode is crucial in the quest for miRNA-based therapeutics to treat neurological disorders. This review aims to shed light on the emerging role of nanotechnology-based approaches using miRNAs to treat neurodegenerative disorders. Nanotechnology encompasses a broad spectrum of applications, one of which is its role in developing nanoscale drug delivery systems. Nanotechnology-based drug delivery systems have attracted the attention of researchers due to the superiority of this mode over conventional treatment systems in terms of their favorable attributes such as bio-compatibility, bio-degradability, extremely small size, and the ability to cross the blood-brain barrier. This review explores nanotechnology-based approaches using miRNAs highlighting the use of viral vectors as well as non-viral vectors (such as exosomes, liposome nanoparticles, gold and magnetic nanoparticles, dendrimer-based nanoparticles, polymeric nanoparticles) to treat neurodegenerative disorders.